Intra-Cellular Therapies
ITCI
#1817
Rank
โ‚ฌ8.63 B
Marketcap
81,48ย โ‚ฌ
Share price
-0.21%
Change (1 day)
52.30%
Change (1 year)

Revenue for Intra-Cellular Therapies (ITCI)

Revenue in 2024 (TTM): โ‚ฌ0.56 Billion

According to Intra-Cellular Therapies's latest financial reports the company's current revenue (TTM ) is โ‚ฌ0.58 Billion. In 2023 the company made a revenue of โ‚ฌ0.41 Billion an increase over the revenue in the year 2022 that were of โ‚ฌ0.23 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Intra-Cellular Therapies from 2014 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) โ‚ฌ0.56 B34.03%
2023 โ‚ฌ0.41 B80.01%
2022 โ‚ฌ0.23 B221.91%
2021 โ‚ฌ72.14 M293.87%
2020 โ‚ฌ18.31 M33754.44%
2019 โ‚ฌ0.05 M
2018 N/A
2017 N/A
2016 N/A-100%
2015 โ‚ฌ0.02 M-93.77%
2014 โ‚ฌ0.45 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
โ‚ฌ0.95 M-99.84%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ9.68 M-98.34%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.12 B-78.19%๐Ÿ‡บ๐Ÿ‡ธ USA